Brazikumab

Last updated
Brazikumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IL23
Clinical data
Other namesMEDI2070
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6410H9830N1718O2016S50
Molar mass 144820.16 g·mol−1

Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease. [1] [2] It targets IL-23. [3]

This drug was developed by MedImmune.

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association
  2. ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  3. ↑ Hanžel J, D'Haens GR (April 2020). "Anti-interleukin-23 agents for the treatment of ulcerative colitis". Expert Opinion on Biological Therapy. 20 (4): 399–406. doi: 10.1080/14712598.2020.1697227 . PMID   31760827.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.